Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC

Published:2019-10 Issue:10 Volume:14 Page:1794-1806
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Antonia Scott J.,Balmanoukian Ani,Brahmer Julie,Ou Sai-Hong I.,Hellmann Matthew D.,Kim Sang-We,Ahn Myung-Ju,Kim Dong-Wan,Gutierrez Martin,Liu Stephen V.,Schöffski Patrick,Jäger Dirk,Jamal Rahima,Jerusalem Guy,Lutzky Jose,Nemunaitis John,Calabrò Luana,Weiss Jared,Gadgeel Shirish,Bhosle Jaishree,Ascierto Paolo A.,Rebelatto Marlon C.,Narwal Rajesh,Liang Meina,Xiao Feng,Antal Joyce,Abdullah Shaad,Angra Natasha,Gupta Ashok K.,Khleif Samir N.,Segal Neil H.

Funder

Bristol-Myers Squibb

Novartis

Merck

Boehringer Ingelheim

AstraZeneca

Bayer

Genentech

Roche

Lilly

Pfizer

Eisai

Exelixis

PharmaMar

Celgene

MedImmune

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference35 articles.

1. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer;Brahmer;N Engl J Med,2015

2. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer;Borghaei;N Engl J Med,2015

3. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer;Reck;N Engl J Med,2016

4. Atezolizumab versus docetaxel for patients with previously treated non–small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial;Fehrenbacher;Lancet,2016

5. Pembrolizumab for the treatment of non–small-cell lung cancer;Garon;N Engl J Med,2015

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer;Gynecologic Oncology;2024-09

2. Durvalumab supplementation for non-small-cell lung cancer: a meta-analysis study;Journal of Cardiothoracic Surgery;2024-07-04

3. Analysis of clinical efficacy and long-term prognosis of patients with hepatocellular carcinoma treated with PD-L1 inhibitor targeting;Technology and Health Care;2024-05-16

4. Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation;Archives of Pathology & Laboratory Medicine;2024-04-16

5. Prediction performance comparison of biomarkers for response to immune checkpoint inhibitors in advanced non‐small cell lung cancer;Thoracic Cancer;2024-03-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3